Antibody-Drug Conjugates as Cancer Therapeutics: Past, Present, and Future.

Vezina, Heather E; Cotreau, Monette; Han, Tae H; Gupta, Manish

Vezina, Heather E; Cotreau, Monette; Han, Tae H; Gupta, Manish.

Affiliation

Vezina HE; Bristol-Myers Squibb, Princeton, NJ, USA.
Cotreau M; ImmunoGen, Inc., Waltham, MA, USA.
Han TH; AbbVie Stemcentrx LLC, South San Francisco, CA, USA.
Gupta M; Bristol-Myers Squibb, Princeton, NJ, USA.

J Clin Pharmacol ; 57 Suppl 10: S11-S25, 2017 Oct.

Article in En | MEDLINE | ID: mdl-28921650

Subject(s)

Antibodies, Monoclonal/administration & dosage; Antineoplastic Agents/administration & dosage; Immunoconjugates/administration & dosage; Neoplasms/drug therapy; Animals; Antibodies, Monoclonal/adverse effects; Antibodies, Monoclonal/pharmacology; Antineoplastic Agents/adverse effects; Antineoplastic Agents/pharmacology; Drug Design; Humans; Immunoconjugates/adverse effects; Immunoconjugates/pharmacology; Neoplasms/immunology

Key words

antibody-drug conjugates; clinical pharmacology; clinical trials; immunopharmacology; immunotherapy; oncology; pharmacokinetics and drug metabolism; pharmacology

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Immunoconjugates / Antibodies, Monoclonal / Neoplasms / Antineoplastic Agents Type of study: Prognostic_studies Limits: Animals / Humans Language: En Journal: J Clin Pharmacol Year: 2017 Document type: Article Affiliation country: United States Country of publication: United kingdom

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google